Skip to search formSkip to main contentSkip to account menu

favipiravir

Known as: 6-Fluoro-3-hydroxy-2-pyrazinecarboxamide, T-705, T-705 cpd 
A pyrazinecarboxamide derivative with activity against RNA viruses. Favipiravir is converted to the ribofuranosyltriphosphate derivative by host… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

AmidesPyrazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Favipiravir: A Potential Antiviral for COVID-19?
Researchers review the evidence for testing various drugs in treating COVID-19. Among the drugs reviewed is favipiravir, also… 
2020
2020
FAVIPIRAVIR AS A POTENTIAL DRUG IN THE TREATMENT OF COVID-19
Favipiravir is a drug developed for use against influenza and has been used successfully in other infectious conditions. After… 
2019
2019
T‐705‐modified ssRNA in complex with Lassa virus nucleoprotein exhibits nucleotide splaying and increased water influx into the RNA‐binding pocket
Lassa virus infection is clinically characterized by multiorgan failure in humans. Without an FDA‐approved vaccine, ribavirin is… 
2019
2019
Growth activation of influenza virus by trypsin and effect of T-705 (favipiravir) on trypsin-optimized growth condition.
Influenza virus is activated by proteolytic cleavage of hemagglutinin by trypsin. After determining the optimal trypsin… 
2019
2019
Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model
Background Influenza B virus infections remain insufficiently studied and antiviral management in immunocompromised patients is… 
2018
2018
Evaluation of in vitro inhibitory potential of type-I interferons and different antiviral compounds on rabies virus replication.
2018
2018
Identification of tell-tale patterns in the 3′ non-coding region of hantaviruses that distinguish HCPS-causing hantaviruses from HFRS-causing hantaviruses
Hantaviruses are negative-sense, single-stranded RNA viruses with small (S)-, middle (M)-, and large (L)-segments. Each segment… 
2015
2015
Drug trials in the hot zone.
  • C. Sansom
  • Lancet. Infectious Diseases (Print)
  • 2015
  • Corpus ID: 206153998
2009
2009
Notice of Start of Phase III Clinical Trials of T-705 as a treatment for influenza infections in Japan
A viral RNA polymerase inhibitor, T-705 was discovered by Toyama Chemical. Having identified a novel mechanism of action, Toyama… 
2008
2008
T-705, A Novel Anti-Influenza Virus Compound - the Safety, Tolerability and Pharmacokinetics in Human
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)